

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

93886

Licensee		In accordance with letter dated August 21, 1992	
1. Lee's Summit Hospital		3. License number 24-24660-01 is in amended its entirety to read as follows:	
2. 530 N. Murray Road Lee's Summit, MO 64063		4. Expiration date April 30, 1996	
		5. Docket or Reference No 030-29074	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding Xenon-133)	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma)	C. As needed	
D. Any byproduct material identified in 10 CFR 35.500	D. Sealed sources identified in 10 CFR 35.500	D. As needed	
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed	

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200 (excluding xenon-133).

9302260030 920908
PDR ADOCK 03029074
C PDR

COPY

236
ML
DH

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
24-24660-01

Docket or Reference number
030-29074

Amendment No. 05

9. (Continued)

- C. Medical use described in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).
- D. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.
- E. In vitro studies.

CONDITIONS

- 10. Location of Use: 530 N. Murray Road, Lee's Summit, Missouri.
- 11. Radiation Safety Officer: Dennis M. Wilcox, M.D.
- 12. Authorized Users:
 - A. John E. Gustafson, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
 - B. David E. Huzuka, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
 - C. Robert G. Schwegler, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
 - D. John E. Scott, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
 - E. Stephen R. Kunz, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
 - F. William M. Chase, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
 - G. Thomas E. Mais, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133) and 31.11.

COPY

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

24-24660-01

Docket or Reference number

030-29074

Amendment No. 05

12. (Continued)

- H. Gwendolyn R. Arnett, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
- I. Sandra K. Heard, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133) and 31.11.
- J. Dennis M. Wilcox, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
- K. Robert Thompson, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
- L. Richard L. Cronemeyer, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
- M. Jack L. Stuber, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.
- N. Owen D. Maddox, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

13. Pursuant to Title 10, Chapter I, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.
14. The licensee shall maintain records of information important to safe and effective decommissioning at the address in Condition 10, per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.
15. This license is based on the licensee's statements and representations listed below:

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
24-24660-01

Docket or Reference number
030-29074

Amendment No. 05

15. (Continued)

A. Letters dated February 20, 1991 (with attachments) and August 21, 1992.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date September 8, 1992

By

Pete J. Lee
Materials Licensing Section, Region III

COPY


```

1      (FOR LFMS USE)
2      INFORMATION FROM LTS
3
4
5
6      PROGRAM CODE: 02120
7      STATUS CODE: 0
8      FEE CATEGORY: 7C
9      EXP. DATE: 19960430
10     FEE COMMENTS: CODE 23
11     DECOM FIN ASSUR REQD: N
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

```

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

```

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 19960430
FEE COMMENTS: CODE 23
DECOM FIN ASSUR REQD: N

```

A. REGION 10

2. FEE ATTACHED: 7 460.
AMOUNT:
CHECK NO.: 100279

SIGNED *James B. C. Duff*
DATE *25 3 22*

1. FEE CATEGORY AND AMOUNT: 7C \$430

3. OTHER

Ante Jacques
3/28/99

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02120
STATUS CODE: 0
FEE CATEGORY: 7C
EXP. DATE: 19960430
FEE COMMENTS: CODE 23
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: LEE'S SUMMIT HOSPITAL
RECEIVED DATE: 920824
DOCKET NO: 3029074
CONTROL NO.: 393886
LICENSE NO.: 24-24660-01
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: 746.00
CHECK NO.: 1002279

3. COMMENTS

SIGNED
DATE

James Lee C. Davis

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 1st ENTERED /_/_/)

1. FEE CATEGORY AND AMOUNT: _____

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT _____
RENEWAL _____
LICENSE _____

3. OTHER _____

SIGNED
DATE

VOUCHER COVER SHEET

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
1	LEES SUMMIT HOSPITAL																								
2	ATTN DOYLE CANTRELL																								
3	DIRECTOR DPT RAD																								
4	536 NW MURRAY ROAD																								
5	LEES SUMMIT MO 64081																								
6	OURPYMT FEE APPL DTD																								
7	8/21/92 FOR 24-24660-01																								
8	CHECK 100879																								

ACCOUNT NO: AA905 AMD

CD NO:

FEE CATEGORY: 7C

CONTROL NO: 393886

DATE RECEIVED: 8/26/92

CHECK AMOUNT: \$460.00

AMOUNT RETAINED: \$430.00

AMOUNT REFUNDED: \$30.00

COMMENTS:

31X6875

GOVERNMENT CODE:

Y

N

DOCUMENT NUMBER	
TRANSACTION CODE	AMOUNT
B&R NUMBER	
FIN	
FEE RETAINED CODE 303	FEE PAID CODE 410
DISCOUNT (CODE 000) TAKEN	DISCOUNT (CODE 415) LOST
AMOUNT PAID \$30.00	
FINAL Y N	

SIGNED: M. Kussie

DATE: 8/26/92

Lee's Summit Hospital

530 N.W. Murray Rd.
Lee's Summit, MO 64081
(816) 525-2950

Log *Aug 21 1992*
Remitter
Check No. *100879*
Amount *2460.00* *referred*
Fee Category *19*
Type of Fee *amc*
Date Check Rec'd. *8/26/92*
Date Completed *8/28*
By: *[Signature]*

August 21, 1992

U.S. Nuclear Regulatory Commission
Regional Licensing Section
799 Roosevelt Road
Glen Ellyn, IL 60137

Re: Amendment of License #24-24660-01

Gentlemen:

We wish to amend the license number referenced above issued to Lee's Summit Hospital, Lee's Summit, Missouri, as indicated below.

1. We wish to delete M.C. Jones, M.D. as an authorized user on our license. Dr. Jones is no longer associated with our facility.
2. We wish to add Jack L. Stuber, M.D. as an authorized on our license. Dr. Stuber is currently listed on the Kansas Radioactive Materials License, No. 19-C264-01, issued to Shawnee Mission Medical Center, Overland Park, Kansas.
3. We wish to add Owen D. Maddox, M.D. as an authorized user on our license. Dr. Maddox is currently listed on the Missouri Radioactive Materials License, No. 24-18818-01, issued to Medical Center of Independence, Independence, Missouri.
4. We wish to have the Hot Lab moved from its current location in the Scanning Room into a storage area across the hall from Nuclear Medicine. We have enclosed a diagram of the Hot Lab area. This area will be locked when not in use. It will also be included in our weekly and daily surveys.
5. We are replacing our Siemens Gamma camera with a Toshiba 901 GCA Gamma camera/computer system.

We are under a fairly strict timetable for construction/equipment installation. We wish to have this request for the Hot Lab expedited, if at all possible, so that the Hot Lab can be moved for the construction.

Member of Health Midwest

RECEIVED

AUG 24 1992

REGION III

AUG 24 1992

93886

PM: 8-21-92

CONTROL NO.

U.S. Nuclear Regulatory Commission
August 21, 1992
Page 2

We have enclosed a check for \$460.00.

If you have any questions concerning this letter or if we can be of any further assistance in this matter, please do not hesitate to call.

Sincerely,



Doyle Cantrell, Director
Department of Radiology

CONTROL NO. 93886

STATE OF KANSAS
RADIOACTIVE MATERIALS LICENSE

Supplementary Sheet

License Number 19-C264-01

Amendment No. 35

Shawnee Mission Medical Center
9100 W. 74th Street
Box 2923
Shawnee Mission, KS 66201

License number 19-C264-01 is hereby amended as follows:

TO READ:

19. Radioactive materials shall be used by, or under the supervision of:

William Halleran, M.D.
Charles Karlin, M.D.
Jack Stuber, M.D.
Robert Moffat, M.D.
Michael Brun, M.D.Michael Dennis, M.D.
William Smith, M.D.
Michael Gaughan, M.D.
Joseph Peter Yut, M.D.
Mark A. Perry, M.D.

TO ADD:

14. (b) The letter dated April 20, 1992, signed by Roger Strobel, with attachment.
- (c) The letter dated May 5, 1992, signed by Roger Strobel.

CONTROL NO

93886

Date MAY 11 1992

FOR THE STATE DEPARTMENT OF HEALTH & ENVIRONMENT

BY

Gerald W. Allan

Radiation Control Program

NRC FORM 374
(10-88)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES

MATERIALS LICENSE

Amendment No. 05

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Medical Center of Independence

2. 17203 E. 23rd Street
Independence, MO 64057In accordance with letter dated
January 27, 19923. License number 24-18818-01 is amended in its
entirety to read as follows:

4. Expiration date December 31, 1995

5. Docket or
Reference No. 030-142136. Byproduct, source, and/or
special nuclear material7. Chemical and/or physical
form8. Maximum amount that licensee
may possess at any one time
under this licenseA. Any byproduct material
identified in 10 CFR
35.100A. Any radiopharmaceutical
identified in 10 CFR
35.100

A. As needed

B. Any byproduct material
identified in 10 CFR
35.200B. Any radiopharmaceutical
identified in 10 CFR
35.200 (excluding
xenon-133)

B. As needed

C. Any byproduct material
identified in 10 CFR
35.300C. Any radiopharmaceutical
identified in 10 CFR
35.300

C. As needed

D. Any byproduct material
identified in 10 CFR
35.400D. Any brachytherapy source
identified in 10 CFR
35.400

D. As needed

E. Any byproduct material
identified in 10 CFR
35.500E. Sealed sources identified
in 10 CFR 35.500

E. As needed

F. Any byproduct material
identified in 10 CFR
31.11

F. Prepackaged Kits

F. As needed

COPY

CONTROL NO

93886

NRC Form 374A
(2-84)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 3 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

24-18818-01

Docket or Reference number

040-14213

Amendment No. 05

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200 (excluding xenon-133).
- C. Medical use described in 10 CFR 35.300.
- D. Medical use described in 10 CFR 35.400.
- E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.
- F. In vitro studies.

CONDITIONS

10. Location of Use: 17203 E. 23rd Street, Independence, MO 64057.
11. Radiation Safety Officer: John E. Scott, M.D.
12. Authorized Users:
- A. Eugene Peterson, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding thyroid carcinoma therapy) and 35.500.
- B. Jon Gustafson, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding thyroid carcinoma therapy) and 35.500.
- C. John E. Scott, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 and 35.500.
- D. Robert G. Schwegler, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding thyroid carcinoma therapy) and 35.500.
- E. David F. Hazuka, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding thyroid carcinoma therapy) and 35.500.
- F. Steven R. Kunz, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding thyroid carcinoma therapy) and 35.500.

CONTROL NO.

93886

COPY

RC Form 374A
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 3 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

24-18818-01

Docket or Reference number

030-14213

Amendment No. 05

12. (Continued)

G. M. C. Jones, Jr., M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding thyroid carcinoma therapy), 35.500 and 31.11.

H. Richard A. Morrison, M.D., for material in 35.400.

I. Thomas E. Mais, M.D., for material in 35.100, 35.200 (excluding xenon-133), 35.500 and Soluble Phosphorus-32 for therapy.

J. William M. Chase, M.D., for material in 35.100, 35.200 (excluding xenon-133), 35.300 and 35.500.

K. Gwendolyn Arnett, M.D., for material in 35.100, 35.200 (excluding xenon-133), 35.300 and 35.500.

L. Dennis Wilcox, M.D., for material in 35.100, 35.200 (excluding xenon-133), 35.300 and 35.500.

M. Sandra Heard, M.D., for material in 35.100, 35.200 (excluding xenon-133) and 35.500.

N. Robert F. Thompson, M.D., for material in 35.100, 35.200 (excluding xenon-133), 35.300 and 35.500.

O. Richard L. Cronmeyer, M.D., for material in 35.100, 35.200 (excluding xenon-133), 35.300 and 31.11.

P. Owen D. Maddox, M.D., for material in 35.100, 35.200 (excluding xenon-133), 35.300 and 35.500.

14. The licensee shall maintain records of information important to safe and effective decommissioning at the location listed in Condition 10. of this license per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

15. This license is based on the licensee's statements and representations listed below:


A. Application dated April 18, 1990.

For the U.S. Nuclear Regulatory Commission

Date: _____


FEB 25 1992

By


Materials Licensing Section, Region III

CONTROL NO. ***END*** 93886

PROPOSED NUCLEAR MEDICINE HOT LAB
LEE'S SUMMIT HOSPITAL
LEE'S SUMMIT, MD



- 1) LEAD BRICK STORAGE AREA
- 2) L-BLOCK
- 3) DOSE CALIBRATOR

SEP 11 1992

Lee's Summit Hospital
ATTN: Doyle Cantrell
530 N. Murray Road
Lee's Summit, MO 64063

Dear Mr. Cantrell:

Enclosed is Amendment No. 05 to your NRC License No. 24-24660-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. You must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Possess radioactive material only in the quantity and form indicated in your license.
3. Use radioactive material only for the purpose(s) indicated in your license.
4. Notify NRC in writing of any change in mailing address.
5. Request and obtain appropriate amendment if you plan to change ownership of your organization, change locations of radioactive material, or make any other changes in your facility or program which are contrary to your license conditions or representations made in your license application and any supplemental correspondence with NRC. Any amendment request should be accompanied by the appropriate fee specified in 10 CFR Part 170.
6. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.
7. Request termination of your license if you plan to permanently discontinue activities involving radioactive material prior to your expiration date.

93886

Lee's Summit Hospital

2

SEP 11 1992

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations in your license application will result in enforcement action against you in accordance with the General Policy and Procedures for NRC Enforcement Actions, 10 CFR Part 2, Appendix C.

If you have any questions or require clarification of any of the above stated information, contact us at (708) 790-5625.

Sincerely,

Original Signed By
Peter J. Lee, Ph.D.
Materials Licensing Section

Enclosure: Amendment No. 05

R111

Lee/bt
09/8/92